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Abstract 
Immunization of mice with plasmids containing genes of Trypanosoma cruzi induces protective 
immunity  in  the  murine  model  of  Chagas  disease.  A  cDNA  clone  that  codes  for  an 
amastigote-specific surface protein (TcSSP4) was used as a candidate to develop a DNA 
vaccine. Mice were immunized with the recombinant protein rTcSSP4 and with cDNA for 
TcSSP4, and challenged with bloodstream trypomastigotes. Immunization with rTcSSP4 pro-
tein makes mice more susceptible to trypomastigote infection, with high mortality rates, 
whereas mice immunized with a eukaryotic expression plasmid containing the TcSSP4 cDNA 
were able to control the acute phase of infection. Heart tissue of gene-vaccinated animals did 
not show myocarditis and tissue damage at 365 days following infection, as compared with 
control animals. INF-γ was detected in sera of DNA vaccinated mice shortly after immun-
ization, suggesting the development of a Th1 response. The TcSSP4 gene is a promising can-
didate for the development of an anti-T. cruzi DNA vaccine. 
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Introduction 
Chagas  disease  caused  by  Trypanosoma  cruzi 
continues  as  a  major  health  problem  in  South  and 
Central America, although the estimated number of 
infected people has fallen from approximately 20 mil-
lion in 1981 to around 10 million in 2009 due to the 
implementation  of  measures  for  vector  control  and 
safer blood transfusions. The risk of transmission of 
the disease is high because the infection has been de-
tected  in  non-endemic  areas  of  the  Americas,  the 
Western  Pacific  Region,  and  the  European  Region 
[1-4].  
The development of anti-T. cruzi vaccines could 
contribute significantly to controlling transmission of 
Chagas disease [5]. It has been shown that immuniza-
tion with plasmids containing T. cruzi genes induces 
immune responses able to protect against lethal infec-
tion with T. cruzi [5–11]. The immune responses in-
duced by DNA immunization are mediated by anti-
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bodies,  CD4+,  and  CD8+  T  cells.  Th1  cytokines  se-
creted by CD4+ T cells stimulate macrophages’ phag-
ocytic activity, B-cell proliferation and antibody pro-
duction.  Additionally,  increased  cytolysis  of  para-
site-infected  cells  by  CD8+  T  cells  and  secretion  of 
cytokines  (INF-γ)  that  may  induce  trypanocidal  ac-
tivity have been described [12–14]. The crucial role of 
CD8+  T  cells  to  control  T. cruzi  infection  has  been 
demonstrated from studies showing the inability of 
mice lacking CD8+ T cell to survive infection (15-17), 
and the ability to increase the level of resistance to 
infection  by  boosting  CD8+  T  cell  responses  with 
strong  immunodominant  epitopes  from  the 
trans-sialidase family [18-21]. 
 To date, DNA immunization protocols against 
T.  cruzi  infection  have  used  genes  associated  with 
trypomastigotes  in  experimental  models.  However, 
the study and characterization of DNA vaccines from 
genes expressed by amastigotes, the form that multi-
plies inside the host cells, have been recently initiated 
[10,11]. We have identified a cDNA clone that codes 
for  an  amastigote-specific  surface  protein  (TcSSP4). 
The recombinant protein MBP::SSP4 was able to in-
duce  macrophage  nitric  oxide  production.  This  re-
combinant protein was also shown to induce the ex-
pression  of  IL-1α,  IL-6,  IL-12,  IFN-γ,  and  TNF-α  in 
macrophages from normal mice, and IL-10 in macro-
phages from immunized mice, suggesting that TcSSP4 
protein  could  participate  in  the  immunoregulatory 
process during Chagas’ disease [22]. In this work we 
first analyzed the effect of a single dose of the recom-
binant protein rTcSSP4 on the course of parasitemia 
and  survival  of  trypomastigote  infected  mice,  and 
then we analyzed the potential of the gene TcSSP4 as a 
DNA vaccine. 
Materials and Methods 
Parasites 
The H8 strain of T. cruzi [A gift from Dr. Jorge E. 
Zavala Castro, Centro de Investigaciones Regionales 
“Dr.  Hideyo  Noguchi”,  Universidad  Autónoma  de 
Yucatán, Mérida, Yucatán, México] was maintained in 
vivo by serial passages of blood form trypomastigotes 
in BALB/c mice and by weekly in vitro passages of 
epimastigotes in Liver Infusion Tryptose (LIT) with 10 
% of fetal calf serum (Gibco, Invitrogen), as described 
[22]. 
Plasmid construction and recombinant protein 
expression and purification 
DNA  encoding  for  the  TcSSP4  protein  (Gene-
BankTM  database  accession  number  AF480943)  was 
obtained from the plasmid pMAL-TcSSP4 [22] as a 2.2 
Eco  RI  fragment  and  ligated  in  the  Eco  RI  site  of 
plasmids  pBk-CMV  (Stratagene,  La  Jolla  ,  CA)  and 
pTWIN1 (New England BioLabs) for construction of 
DNA  vectors  pBCSSP4  and  pTWSSP4,  respectively. 
The plasmid pTWIN1 was used in order to obtain the 
recombinant  protein  TcSSP4  (rTcSSP4)  without  the 
MBP  tag.  Purification  of  the  recombinant  protein 
rTcSSP4 was achieved by transforming the plasmid 
pTWSSP4 into E. coli BL21(DE3). Cells were grown at 
37 C to OD595 = 0.5 and induced with 0.3 mM IPTG 
for 6 h, then harvested by centrifugation and lysed by 
sonication in the presence of 10 μg/ml lysozyme. The 
expressed rTcSSP4 protein was purified from the ly-
sate  by  using  a  chitin-affinity  column,  followed  by 
intein cleavage by temperature shift from 4 C to 25 C 
at pH 7.0, according to the manufacturer's protocol. 
Analysis  of  protein  purification  was  carried  out  by 
10% SDS-PAGE and Coomassie blue staining. 
Immunization and trypomastigote infection of 
mice 
Female 6–8-week old BALB/c mice were main-
tained according to the recommendations of our In-
stitutional  Animal  Care  and  Use  Committee.  For 
protein  immunization,  each  mouse  was  immunized 
i.p.  with  10  μg  of  rTcSSP4  protein  emulsified  with 
Freund’s  complete  adjuvant  (Sigma,  St  Louis,  MO). 
DNA immunizations were done twice at 2 week in-
tervals in the tibialis anterioris muscle with the plas-
mids  pBCSSP4  or  pBk-CMV  resuspended  in  PBS. 
Mice  immunized  with  the  rTcSSP4  protein  were 
challenged i.p. with 1x104 or 3x104 bloodstream try-
pomastigotes  (BT)  3  or  7  days  post-immunization. 
Mice immunized with DNA were challenged 2 weeks 
after the last immunization with 1x104 BT. Parasitemia 
was monitored every 3 days. All mice were randomly 
assigned  into  control  or  vaccinated  groups  of  four 
mice each in two independent experiments (n=8). 
Histopatology 
Hearts from infected mice were removed, rinsed 
with PBS, and fixed for 24 h in 4% paraformaldehyde 
in PBS (pH 7.4). Fixed hearts were embedded in par-
affin,  sectioned  (6  μm),  stained  with  hematoxy-
lin-eosin, and examined by light microscopy (Nikon 
Eclipse E600, Nikon, Japan). 
Serum cytokine analysis 
Sera of mice immunized with DNA or rTcSSP4 
protein were collected at 3 and 12 h after the last im-
munization.  Pools  of  sera  from  each  group  of  im-
munized mice were analyzed for the presence of IL-2, 
IL-4, IL-6, IL-10, TNF-, and IFN- with commercially 




Mouse,  PharMingen,  San  Diego,  CA).  Microwell 
plates  (96-wells,  Nunc  Maxisorp)  were  coated  with 
capture antibody diluted (1:250) in coating buffer (0.2 
M sodium phosphate, pH 6.5 or 0.1 M sodium car-
bonate,  pH  9.5),  and  incubated  overnight  at  4  °C. 
Wells were washed with PBS containing 0.05% Tween 
20. Plates were blocked with 10% fetal bovine serum 
in PBS, incubated at room temperature for 1 h, and 
washed with PBS. Sera (1:8) and recombinant stand-
ards were added, and plates were incubated for 2 h at 
room temperature. After washing, detection antibody 
plus avidin-HRP were added to each well. Plates were 
incubated for 1 h at room temperature, washed, and 
developed  with  ABTS  (Zymed  Laboratories,  South 
San Francico, CA) to record the OD at 405 nm.  
Statistical analysis 
Results were expressed as means ± SD. Statistical 
analysis was performed using one-way ANOVA fol-
lowed by Tukey’s test. The survival time was calcu-
lated by the Kaplan-Meier method. Differences were 
considered to be statistically significant when the p 
value was <0.01 or <0.05. 
Results  
Immunization with rSSP4 increases para-
sitemia and mortality in the murine model. 
Proliferation of spleen cells, from immunized or 
normal mice, stimulated in vitro with ConA or with 
the homologous antigen, was suppressed by the fu-
sion protein MBP::SSP4. This suppression was inhib-
ited by L-NAME [22], which indicates that nitric oxide 
is involved in suppressing spleen cells proliferation as 
it has been shown [23, 24]. On the other hand, mice 
peritoneal  macrophages  (pMΦs)  obtained  3  and  7 
days  after  immunization  with  a  single  dose  of 
MBP::SSP4  showed  high  and  null  nitric  oxide  pro-
duction  respectively  compared  with  pMΦs  from 
normal  mice  [22].  Therefore  we  investigated  para-
sitemia and mortality in mice immunized with a sin-
gle dose of the recombinant protein rTcSSP4 and then 
challenged  with  bloodstream  trypomastigotes  at  3 
and 7 days post-immunization. 
 The recombinant protein was purified from the 
intein-TcSSP4 fusion protein bound to chitin beads by 
temperature  shift.  Figure  1,  lane  2  shows  the  Coo-
massie blue staining of the 60 kDa purified protein 
that  was  used  to  immunize  the  mice.  To  analyze 
whether immunization induced immunosuppression, 
mice were challenged with T. cruzi trypomastigotes. 
Both parasitemia and death rate were evaluated 3 and 
7  days  after  a  single  immunization  with  10  μg  of 
rTcSSP4. In mice challenged at both times after im-
munization with 3x104 trypomastigotes, (Fig. 2A, ●, 
○), the parasitemia starts earlier than in normal ani-
mals  (Fig.  2A,  ▼).  Although  a  peak  of  parasitemia 
was  observed  at  day  26  in  normal  animals,  all  im-
munized mice died before a peak was reached. Death 
occurred  at  day  14  in  those  mice  infected  7  days 
post-immunization (Fig. 2B, ○) and at day 17 in those 
infected 3 days after immunization (Fig. 2B, ●). De-
spite the peak of parasitemia shown by normal ani-
mals, they began dying at day 24 after challenge (Fig. 
2B, ▼). 
When  the  challenge  dose  of  parasites  was  re-
duced to 1x104 (Fig. 2C and D), the beginning of par-
asitemia was similar in all animals and they presented 
the parasitemia peak at the same time. However, in 
immunized mice the peak was higher than in normal 
animals (Fig. 2C, ●, ○). In spite of a higher mortality 
than in normal animals, the survival rate was higher 
(p<0.05) when compared to mice infected with 3x104 
trypomastigotes (Fig. 2 B and D), suggesting that the 
lower  number  of  parasites  allowed  them  to  better 





Figure  1.  Purification  of  the  rTcSSP4  protein.  rTcSSP4 
protein was purified from the Intein-TcSSP4 fusion protein 
bound to chitin beads by temperature shift from 4 C to 25 
C at pH 7.0. (1) Molecular weight markers and (2) purified 







Figure 2. Parasitemia and mortality of rTcSSP4 immunized mice challenged with BT. Mice were immunized with a single 
dose of rTcSSP4 (10 μg), and at 3 (●) or 7 (○) days post-immunization (PI) animals were infected with 3 x 10
4 (A and B) or 
1 x 10
4 (C and D) BT. Parasitemia (A and C) and mortality (B and D) rates were recorded up to 45 days. Normal animals 
received only Freund’s complete adjuvant (▼). Parasitemia values represent mean ± standard errors of the means for 
surviving mice. 
 
Intramuscular immunization with anti-
gen-expressing DNA plasmid induces protec-
tion against T. cruzi infection. 
 DNA immunization is a widely used procedure. 
DNA codified proteins are internally processed and 
presented  by  MHC  class  I  and  II  antigens,  and  are 
therefore able to induce a Th1 type immune response 
in which CD8+ T cells are activated [25]. In mice vac-
cinated  with  the  plasmid  pBCSSP4  and  later  chal-
lenged with  T. cruzi parasites, the parasitemia peak 
was observed at day 25 with the lowest number of 
parasites (Fig. 3A, ●), in comparison with the para-
sitemia peak of mice immunized with control plasmid 
pBk-CMV (29 days) (Fig. 3A, ○), or animals injected 
with PBS (25 days) (Fig. 3 A, ▼). Statistically signifi-
cant  differences  (p<0.01)  were  found  in  the  para-
sitemia peak between vaccinated and control mice. In 
terms  of  survival,  the  group  immunized  with 
pBCSSP4  showed  the  highest  survival  rate  (~75%) 
even at 1 year after infection (Fig. 3B, ●) (p <0.05). 
Decreased tissue damage in mice immunized 
with pBCSSP4. 
Heart  tissue  damage  was  analyzed  after  long 
term  infection  of  immunized  mice.  One  year  after 
initial  infection,  surviving  animals  were  sacrificed. 
Hearts were dissected and analyzed for the presence 
of myocarditis and tissue damage. No damage was 
found in hearts from mice immunized with the plas-
mid pBCSSP4 (Fig. 4A). In contrast, severe myocardi-
tis and tissue damage were observed in hearts from 
mice immunized with the control plasmid pBKCMV 
(Fig.  4B)  or  from  mice  injected  with  PBS  (Fig.  4D). 
Non-immunized,  non-infected  mice  were  used  as 






Figure 3. Parasitemia and mortality of pBCSSP4 immunized mice challenged with BT. Mice were immunized twice 15 days 
apart with 100 μg/dose of the plasmids pBCSSP4 (●) and pBk-CMV (○)., Two weeks after the last immunization they were 
infected with 10
4 BT. Control animals received only PBS (▼). Parasitemia (A) and mortality (B) rates were recorded up to 
365 days. Parasitemia values represent mean ± standard errors of the means for surviving mice. 
 
Figure 4. BALB/c mice immunized with plasmid pBCSSP4 and infected with T. cruzi did not develop myocarditis. BALB/c 
mice immunized with the plasmids pBCSSP4 (A), pBk-CMV (B), or injected with PBS (D) were infected with 10
4 BT. Control 
mice were non-immunized and non-infected (C). At 365 days post-infection, cardiac sections from corresponding mice were 








   
Figure 5. Serum cytokine levels in immunized mice. Pools 
of serum collected 3 (□) and 12 (■) h after final immuniza-
tion and ELISA assays were performed for the presence of 
IL-6 (A), TNF-α (B) and IFN-γ (C). Sera were from mice 
immunized twice 15 days apart, with adjuvant (Adj), rSSP4 
protein (10 μg), plasmid pBk-CMV (100 μg), and plasmid 
pBCSSP4 (100 μg). Values represent the mean ± SD of a 
representative triplicate assay. 
 
Serum cytokine levels in mice immunized with 
rTcSSP4 and pBCSSP4.  
 As a first approach to analyze why protein or 
DNA vaccinated mice died or survived respectively, 
the  serum  cytokine  profile  of  immunized  mice  was 
analyzed.  Sera  from  immunized  and  control  mice 
were  collected  3  (□)  and  12  (■)  h  after  the  last  im-
munization  and  cytokine  levels  were  measured  by 
ELISA.  When  compared  with  controls,  statistically 
significant  differences  were  found  in  IL-6  levels  in 
mice  immunized  with  either  rTcSSP4  protein  or 
pBCSSP4 plasmid. The IL-6 levels were higher at 3h 
(p<0.01)  and  lower  at  12  h  (p<0.01)  (Fig.  5A).  For 
TNF-α, statistically significant differences were found 
in  mice  immunized  with  rTcSSP4  protein  at  3  h 
(p<0.01) and 12 h (p<0.01) when compared with con-
trol mice, and no significant differences were found in 
mice  immunized  with  pBCSSP4  plasmid  (Fig.  5B). 
However,  a  clear  difference  was  found  regarding 
IFN-γ  production;  only  3  h  sera  from  animals  im-
munized with the pBCSSP4 plasmid showed signifi-
cant amounts of this cytokine. In 12 h sera this cyto-
kine  was  not  detected.  No  detectable  amounts  of 
IFN-γ were found in the other conditions (Fig. 5C). 
Cytokines IL-1, IL-4, and IL-10 were not detected at 
these times of serum collection (data not shown). 
Discussion  
Mice immunized with the rTcSSP4 protein and 
then challenged with a lethal dose of BT showed ear-
lier  parasitemia  and  death  compared  with 
non-immunized  mice.  However,  when  immunized 
animals were challenged with third of the lethal dose 
of parasites, parasitemia started at the same time as in 
non-immunized  animals,  but  peaks  of  parasitemia 
and  death  rates  were  higher  in  immunized  mice. 
These  results  could  be  explained  in  terms  of  im-
munossuppression and parasite load. We have pre-
viously shown that the fusion protein MBP::SSP4 was 
able to induce nitric oxide (NO) production by spleen 
and  peritoneal  macrophages  (pMφs).  Also  we  ob-
served that this protein suppresses spleen cell prolif-
eration. pMφs from normal mice as well as those that 
recovered 3 and 5 days after one immunization with 
MBP::SSP4  were  able  to  synthesize  NO,  whereas 
pMφs recovered at 7 days after one immunization and 
3, 5 and 7 days after two immunizations were not able 
to  produce  NO.  This  recombinant  protein  was  also 
shown to induce the expression of IL-1α, IL-6, IL-12, 
IFN-γ, and TNF-α in pMφs from normal mice, IL-6, 
TNF-α, and IL-10 in pMφs recovered 3 days after one 
immunization, and IL-6 and IL-10 in pMφs recovered 




Earlier parasitemia and death of mice challenged 
3 days after one immunization could be due mainly to 
NO  production  induced  by  rTcSSP4.  It  has  been 
shown that NO production contributes to the immu-
nosuppression observed during infection with Toxo-
plasma  gondii  [26],  Paracoccidioides  brasiliensis  [27], 
Echinoccocus  multilocularis  [28],  Trypanosoma  brucei 
[29], and Trypanosoma cruzi [30]. Although NO can kill 
intracellular  parasites,  overproduction  can  be  detri-
mental, even lethal, to the host [26, 31]. In addition, 
earlier  parasitemia  and  death  of  mice  challenged  7 
days after one immunization could be due to macro-
phage inactivation by IL-10 [32], and to the beginning 
of a Th2 response induced by rTcSSP4. Suppression of 
immune responses during T. cruzi infection results in 
a significantly increased parasite burden [14]. Thus, 
immunized mice that were able to control the initial 
phase  of  parasitemia  (with  a  lower  dose  of  BT) 
showed a parasitemia peak higher than that observed 
in non-immunized animals. Experiments are required 
to follow the kinetics of the immune response devel-
opment and determine the type of T cells that are in-
duced (Th1 or Th2) when a full immune response has 
been established. 
In  DNA  based  immunization,  the  antigen  en-
coded by plasmid DNA is processed in the cytoplasm 
by transfected cells and presented to elicit an immune 
response  [33].  Mice  immunized  with  the  plasmid 
pBCSSP4, and then challenged with BT showed a re-
duction in parasitemia and 75% survival, as compared 
with  control  animals.  Similar  results  have  been  re-
ported for DNA immunizations with T. cruzi genes, 
showing  a  reduction  of  parasitemia  and  mortality 
(Table 1). Besides using different genes, the variability 
in parasitemia and survival reported in these studies 
could be due to DNA doses, number of doses, interval 
between  doses  and  time  of  challenge  after  the  last 
dose, as well as parasite strain and number of para-
sites used to challenge. Therefore, it is necessary to 
develop  and  standardize  a  protocol  for  DNA  im-
munization in experimental Chagas disease. 
Immunization with pBCSSP4 altered the course 
of disease development in the chronic phase of infec-
tion in our experimental model. Immunized animals 
not  only  survived  the  trypomastigote  infection  but 
also showed low levels of parasitemia, and displayed 
undetectable levels of heart muscle inflammation and 
necrosis in the chronic phase of infection. Similarly, 
reduction in skeletal and heart muscle inflammation 
and  necrosis  in  mice  immunized  with  a  mixture  of 
plasmids  containing  the  ASP-1,  ASP-2  and  TSA-1 
genes  and  with  antigen-encoding  plasmids  plus  in-
terleukin-12,  and  granulocyte-macrophage  colo-
ny-stimulating factor plasmids has been reported [10]. 
These results support the hypothesis that severity of 
the  disease  in  chronic  T.  cruzi  infection  is  tightly 
linked to the relative success in limiting parasite levels 
[14, 34]. 
 
Table 1. DNA vaccines with plasmids containing Trypa-
nosma cruzi genes 
Gene  Survival (%)  Reference 
TSA-1  55–90  5 
CPR  100  7 
KMP11-HSP70  50  8 
TS  100  9 
ASP-1, ASP-2, TSA-1 




Clone 9 (89.9% identity with ASP-2)  100  11 
CRP  100  41 
PFR/PFR3-HSP70  100  42 
LYT1 Plus IL-12  75  43 
TS family members  75  43 
Mucin family members  25  43 




 It has been shown in the murine model that a 
Th1 response is able to control T. cruzi infection and to 
reduce the severity of the disease [35–40]. Although 
inflammatory  cytokines  IL-6  and  TNF-α  were  de-
tected at 3 h and 12 h post-immunization in sera of 
mice  immunized  with  adjuvant,  rTcSSP4  protein, 
pBk-CMV, and pBCSSP4, INF-γ was detected only at 
3  h  post-immunization  in  sera  of  mice  immunized 
with  pBCSSP4.  These  results  suggest  that  mice  im-
munized with the gene coding for the TcSSP4 protein 
are primed to develop a Th1 response. Experiments 
are being conducted, varying the number of doses of 
plasmid DNA and parasites, to determine the type of 
response just before parasite challenge. 
 In summary, we have shown that immunization 
with rTCSSP4 protein makes mice more susceptible to 
trypomastigote infection, and a genetic vaccine based 
on TcSSP4 cDNA provides partial protection against 
lethal infection  with T. cruzi. Further investigations 
are needed to determine whether different DNA im-
munization protocols (e.g. total DNA dose, number 
and interval between doses, time of challenge, cyto-
kine adjuvants) might yield better protection.  
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